Whether immunotherapy is recommended for gastric cancer is related to the immune status of patients suffering from gastric cancer, the molecular subtype of the tumor, etc. At present, immunotherapy for gastric cancer is commonly used in people with advanced stage, among which PD-1 monoclonal antibody is a commonly used drug. Immunotherapy for gastric cancer is to use the immune system to treat tumors by increasing the ability of the body’s immune system to resist tumors, or increasing the immunogenicity of tumors. Among them, the immune status of the gastric cancer population and the molecular subtypes of the tumors have a more important influence on the treatment effect, and individualized treatment plans need to be developed. Generally, microsatellite instability (MSI) and EBV-associated gastric cancers are more responsive to immunotherapy, and immunotherapy can be applied when the expression of PD-L1 is more than 1%, and the efficacy is better when the expression of PD-L1 is more than 50%. Commonly used immunotherapy methods include immune checkpoint inhibitors, such as PD-1 monoclonal antibody, which are often combined with other chemotherapeutic drugs. It is recommended that gastric cancer patients should consult doctors in time after diagnosis and be evaluated whether immunotherapy is needed by professional doctors according to the disease condition and their own status.